Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are-capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
Abstract: The immunogenic peptide sequence from Echinococcus granulosus antigen 5 is recognized both by sera from patients suffering from hydatidosis and by a monoclonal antibody of isotype IgG1 produced by hybridoma EG 02154/12 and registered with the C.N.C.M. on Jun. 25, 1990 under number 1-957.
Type:
Grant
Filed:
March 10, 1993
Date of Patent:
July 30, 1996
Assignees:
Institut Pasteur, Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale (Inserm)
Inventors:
Brigitte Facon, Mustapha Chamekh, Colette Dissous, Andr e Capron, Andr e Tartar, H el ene Gras-Masse
Abstract: Specific primers useful for the detection of the presence of lecithinase or enterotoxin genes or the presence of Clostridium perfringens bacteria in a sample by a polymerase chain reaction, particularly, in food sample or fecal samples.
Type:
Grant
Filed:
December 22, 1993
Date of Patent:
July 23, 1996
Assignee:
Institut Pasteur and Cneva
Inventors:
Patrick Fach, Jean-Pierre Guillou, Michel Popoff
Abstract: The invention relates to papillomavirus probes derived from new DNA-HPVs deposited with the C.N.C.M. on May 6, 1988, under the following filing numbers:______________________________________ PGEM 4 HPV49: I-754 PSP 65 HPV50: I-755 PSP 64 HPV54: I-756 PGEM 4 HPV55A: I-757 PGEM 4 HPV55B: I-758 ______________________________________These probes can be used for in vitro detection of:in the case of HPV49: warts of the skin (in particular, common and plantar warts) and the differential diagnosis of epidermodysplasia verruciformis,in the case of HPV50: epidermodysplasia verruciformis, intraepithelial neoplasias and cutaneous cancer,in the case of HPV55.sub.-- : genital neoplasias and cancers of the uterine cervix,in the case of HPV55.sub.-- : genital neoplasias and cancers of the uterine cervix, condylomas and papillomas.
Type:
Grant
Filed:
May 10, 1994
Date of Patent:
July 9, 1996
Assignee:
Institut Pasteur
Inventors:
Gerard Orth, Michel Favre, Dina Kremsdorf, Gerard Pehau-Arnaudet
Abstract: DNA probes are capable of hybridizing to a portion of the genome of pathogenic Listeria monocytogenes, but do not hybridize to genomes of other Listeria species and other hemolytic bacteria. These probes are useful to identify food sources infected with Listeria monocytogenes and to distinguish these food sources from those infected with non-pathogenic Listeria species. In addition, methods for the detection of pathogenic Listeria in samples using the disclosed probes are provided. A method of detection using PCR amplification with primers specific for L. monocytogenes DNA is also disclosed.
Abstract: Cell lines which lack human class II histocompatibility antigens are disclosed. The cell lines may be utilized within a method for propagating microorganisms, such as viruses, for determining the presence and/or amount of antibody to a microorganism in a biological fluid, and within a method for producing antibodies to a selected microorganism.
Type:
Grant
Filed:
March 20, 1995
Date of Patent:
May 7, 1996
Assignees:
Genetic Systems Corporation, Institut Pasteur
Inventors:
Robert C. Nowinski, Luc Montagnier, David Klatzmann
Abstract: A recombinant plasmid comprises the cyaC and the cyaA genes of Bordetella which directs the expression of Bordetella, adenylate cyclase in a transformed host cell. A recombinant DNA molecule can comprise the Bordetella cyaA gene containing at least one insertion of a heterologous DNA sequence at at least one permissive site. In addition, a recombinant Bordetella adenylate cyclase comprises a heterologous epitope at a permissive site. Methods of inducing a specific B cell, helper T cell, and CTL cell immune response are provided.
Type:
Grant
Filed:
November 7, 1994
Date of Patent:
April 2, 1996
Assignee:
Institut Pasteur
Inventors:
Daniel Ladant, Claude Leclerc, Peter Sebo, Agnes Ullmann
Abstract: A test kit for the identification of various bacterial species groupings comprises a DNA probe which can identify palindromic units specific to particular bacterial species or species groupings. Such probes are highly specific for particular species or species subgroups. Accordingly, specific identification of bacteria may be achieved.
Type:
Grant
Filed:
December 10, 1993
Date of Patent:
February 20, 1996
Assignee:
Institut Pasteur
Inventors:
Eric Gilson, Jean-Marie Clement, David Perrin, Agnes Ullmann, Maurice Hofnung
Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
Type:
Grant
Filed:
November 5, 1992
Date of Patent:
December 12, 1995
Assignees:
Institut Pasteur, Universite Paris-VI
Inventors:
Bernard Dujon, Andre Choulika, Laurence Colleaux, Cecile Fairhead, Arnaud Perrin, Anne Plessis, Agnes Thierry
Abstract: Character of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.
Type:
Grant
Filed:
January 13, 1993
Date of Patent:
November 28, 1995
Assignee:
Institut Pasteur
Inventors:
Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
Abstract: The invention relates to papillomaviruses, particularly to DNA-HPVs isolated from the papillomaviruses IP5 and IP6, the restriction maps of which are presented in FIGS. 10 and 11, and also to probes containing these DNA-HPVs or fragments obtained from them. The invention relates, in addition, to "kits" containing distinct groups of probes, containing one of these DNA-HPVs or DNA-HPV fragments, as well as a procedure for the detection and identification of papillomaviruses which makes use of these different probes.
Type:
Grant
Filed:
July 16, 1992
Date of Patent:
May 2, 1995
Assignees:
Institut Nationale de la Sante, Institut Pasteur
Inventors:
Sylvie Beaudenon, Dina Kremsdorf, Odile Croissant, Gerard Orth
Abstract: This invention is directed to an isolated antibody specific for gp110 glycoprotein of a human immunodeficiency virus type 1 (HIV-1), and a hybridoma which produces such an antibody. HIV-1 is the causative agent of Acquired Immunodeficiency Syndrome (AIDS).
Type:
Grant
Filed:
September 24, 1992
Date of Patent:
April 18, 1995
Assignee:
Institut Pasteur and Centre National de la Recherche Scientific
Abstract: The invention relates to a hybridization probe for detecting the existence of bacteria in a sample. It consists of one of the two pentadecadeoxyribonucleotides of sequence(5')d - AAG GAG GTG ATC CAG (3'),(5')d - CTG GAT CAC CTC CTT (3').
Type:
Grant
Filed:
January 11, 1993
Date of Patent:
April 18, 1995
Assignees:
Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
Abstract: A compound having the following formula I: ##STR1## in which: R' represents a hydrogen atom or an azido group,alc represents an alkyl group of 1 to 4 carbon atoms, an alkoxy group of 1 to 4 carbon atoms or an amino group.
Type:
Grant
Filed:
January 29, 1990
Date of Patent:
February 28, 1995
Assignee:
Institut Pasteur
Inventors:
Tam Huynh Dinh, Catherine Gouyette, Bernadette Dupraz, Jean Igolen, Nathalie Savatier, Jean-Francois Nicolas, Francoise Barre-Sinoussi
Abstract: A DNA probe is disclosed which is capable of hybridizing to a portion of the genome of pathogenic Listeria monocytogenes but which does not hybridize to portions of the genomes of other Listeria species and other humilytic bacteria. This probe is useful to identify food sources infected with Listeria monocytogenes and to distinguish these food services from those infected nearly with non-pathogenic Listeria species. In addition, methods for the detection of pathogenic Listeria in samples using the disclosed probes are provided.
Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-.beta.. The RAR-.beta.
Type:
Grant
Filed:
July 22, 1993
Date of Patent:
December 27, 1994
Assignee:
Institut Pasteur
Inventors:
Hughes B. De The, Agnes Marchio, Pierre Tiollais, Anne DeJean, Nigel Brand, Martin Petkovich, Andree Krust, Pierre Chambon
Abstract: Protein compositions containing the p18 and p25 proteins of the lymphadenopathy virus are used for detecting antibodies in blood serum as indicative of infection by such virus. The proteins can be used in various conventional ways to perform immunoassays for the detection of the antibodies.
Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency Virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.
Abstract: The glycosylphospholipid nucleoside derivatives of the invention are based on the formula: ##STR1## wherein: R.sub.1 is a nucleoside derivative selected from the group consisting of 3'-azidothymidine (AZT); 2', 3'-dideoxythymidine (ddT); and 2'-deoxy-5-fluorouridine (dFU);R.sub.2 is a hexose or pentose sugar, with the exception of glucose when x is 1;A is a hydrogen atom or an alkyl or alkoxy chain containing from 5 to 20 carbon atoms, said alkyl or alkoxy chain having at its extremity a group selected from the group consisting of a hydrogen atom and an NR'R" group, wherein R' and R" represent hydrogen or an alkyl group of 1 to 4 carbon atoms;x is a number from 1 to 12;y is a number from 1 to 4; andz is 0 or 1; and further wherein:attachment of said hexose sugar is at position 1 or position 6 of said hexose sugar, and attachment of said pentose sugar is at position 1 or position 5 of said pentose sugar.
Type:
Grant
Filed:
September 21, 1992
Date of Patent:
October 25, 1994
Assignee:
Institut Pasteur
Inventors:
Tam Huynh Dinh, Catherine Gouyette, Jean Igolen, Robert Fauve, Luc Montagnier, Yvette Henin, Olivier Schwartz